CRISPR/Cas9 targeting of GPRC6A suppresses prostate cancer tumorigenesis in a human xenograft model.UroTodayY sequence by immunofluorescence. We assessed functions of GPRC6A in PC-3 cells expressing endogenous GPRC6A and in GPRC6A-deficient PC-3 cells … Continue reading
Bioscience TechnologyBringing CRISPR into FocusBioscience TechnologyCRISPR-Cas3 is a subtype of the CRISPR-Cas system, a widely adopted molecular tool for precision gene editing in biomedical research. Aspects of its mechanism of action, however, parti… Continue reading
Seeking Alpha |
Editas Medicine: A Gene Editing Concern To Watch
Seeking Alpha The firm’s CRISPR Cpf1 patent portfolio is advancing nicely, with the European Patent Office recently issuing a notice of intent to grant the Broad Institute broad coverage of CRISPR Cpf1 system for human gene editing, which was exclusively licensed to … |